Search

Kym I Lorrain

from San Diego, CA
Age ~53
Get Report
Also known as:
Kym L Lorrain, Kym I Callahan, Kim I Callahan, Kym Lorrian, Kymmy Callahan, Nancy Hougland
Phone and address:
11286 Crystal Oaks Way, San Diego, CA 92131
(858) 571-3753
Related to:
Kenneth J Spindler, 73Jeffrey M Lorrain, 53Wilfred C Lorrain, 83Massimo M Messina, 60Tamera A Messina, 57Ana G Diaz, 67Tamera A Callahan, 57Stephen P Callahan, 77Jose F Diaz, 70Daniel S Lorrain, 56Carol M Lorrain, 82Gabriella Messina, 66Sean P Callahan, 49
Connected to:
Ann H Lorraine, 86Bob Lorraine, 100Brandon Lorraine, 38Chin A Lorraine, 93Jed S Lorraine, 49Joseph C Lorraine, 85Julia G Lorraine, 76Kemp N Lorraine, 87Lacey D Lorraine, 42Lola Lorraine, 48

Kym Lorrain Phones & Addresses

  • 11286 Crystal Oaks Way, San Diego, CA 92131 (858) 571-3753
  • La Jolla, CA
  • Hillsboro, OR
  • Oceanside, CA

Work

Company: Pipeline therapeutics Jan 2019 Position: Senior scientist ii

Education

School / High School: San Diego State University 1990 to 1995

Industries

Research

Resumes

Resumes

Kym Lorrain Photo 1

Senior Scientist Ii

View page
Location:
San Diego, CA
Industry:
Research
Work:
Pipeline Therapeutics
Senior Scientist Ii
Braincells, Inc. Feb 2005 - Mar 2012
Research Scientist
Inception Sciences, Inc. Feb 2005 - Mar 2012
Research Scientist Ii
Merck 1999 - 2005
Research Associate
Education:
San Diego State University 1990 - 1995

Publications

Us Patents

5 Ht Receptor Mediated Neurogenesis

View page
US Patent:
7678808, Mar 16, 2010
Filed:
May 8, 2007
Appl. No.:
11/746008
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd Carter - San Diego CA, US
Andrew Morse - San Diego CA, US
Kai Treuner - San Diego CA, US
Kym I. Lorrain - San Diego CA, US
Assignee:
BrainCells, Inc. - San Diego CA
International Classification:
A61K 31/44
A61K 31/395
A61K 31/497
A61K 31/501
US Classification:
514280, 51421001, 51421021, 5142222, 5142298, 514247, 51425216, 514359, 514415
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a 5HTR agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Neurogenesis By Modulating Angiotensin

View page
US Patent:
7858611, Dec 28, 2010
Filed:
May 9, 2007
Appl. No.:
11/746539
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd A. Carter - San Diego CA, US
Kai Treuner - San Diego CA, US
Kym I. Lorrain - San Diego CA, US
Assignee:
BrainCells Inc. - San Diego CA
International Classification:
A61K 31/33
A61K 31/401
A61K 31/11
A61K 31/075
US Classification:
514183, 514408, 514423, 514693, 514706, 514315, 514700, 514715
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulation angiotensin activity to stimulate or activate the formation of new nerve cells.

Modulation Of Neurogenesis By Pde Inhibition

View page
US Patent:
7985756, Jul 26, 2011
Filed:
Oct 20, 2006
Appl. No.:
11/551667
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd A. Carter - San Diego CA, US
Kym I. Lorrain - San Diego CA, US
Jammieson C. Pires - San Diego CA, US
Kai Treuner - San Diego CA, US
Assignee:
BrainCells Inc. - San Diego CA
International Classification:
A61K 31/505
A61K 31/40
A61K 31/44
A61K 31/445
US Classification:
514275, 514315, 514354, 514424
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a PDE agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.

Combinations Containing A 4-Acylaminopyridine Derivative

View page
US Patent:
7998971, Aug 16, 2011
Filed:
Jun 21, 2007
Appl. No.:
11/766721
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd A. Carter - San Diego CA, US
Andrew Morse - San Diego CA, US
Kai Treuner - San Diego CA, US
Kym I. Lorrain - San Diego CA, US
Assignee:
BrainCells Inc. - San Diego CA
International Classification:
A61K 31/44
A61K 31/165
A61K 31/47
US Classification:
514292, 514618, 514314
Abstract:
The instant disclosure describes compositions and methods for treating diseases and conditions of the central and peripheral nervous system. The disclosure includes compositions and methods based on use of a 4-acylaminopyridine derivative in combination with one or more other neurogenic agents. One 4-acylaminopyridine derivative is MKC-231.

Methods For Identifying Agents And Conditions That Modulate Neurogenesis

View page
US Patent:
20070015138, Jan 18, 2007
Filed:
Jul 7, 2006
Appl. No.:
11/482528
Inventors:
Carrolee Barlow - Del Mar CA, US
Jammieson Pires - San Diego CA, US
Kym Lorrain - San Diego CA, US
Todd Carter - San Diego CA, US
Kai Treuner - San Diego CA, US
Assignee:
BrainCells, Inc. - San Diego CA
International Classification:
C12Q 1/00
C12N 5/08
US Classification:
435004000, 435368000
Abstract:
Methods and tools for identifying agents and conditions that modulate neurogenesis are disclosed. The disclosure also relates to methods and tools for identifying populations of neural stem cells suitable for transplantation.

Neurogenesis By Muscarinic Receptor Modulation

View page
US Patent:
20070049576, Mar 1, 2007
Filed:
Aug 25, 2006
Appl. No.:
11/467527
Inventors:
Carrolee Barlow - Del Mar CA, US
Tood Carter - San Diego CA, US
Kym Lorrain - San Diego CA, US
Jammieson Pires - San Diego CA, US
Andrew Morse - San Diego CA, US
Dana Gitnick - San Marcos CA, US
Kai Treuner - San Diego CA, US
Alex Broadhead - San Diego CA, US
Assignee:
BrainCells, Inc. - San Diego CA
International Classification:
A61K 31/55
A61K 31/473
A61K 31/4745
A61K 31/445
A61K 31/403
A61K 31/66
US Classification:
514214030, 514295000, 514297000, 514319000, 514411000, 514114000
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Modulation Of Neuorgenesis By Hdac Inhibition

View page
US Patent:
20070078083, Apr 5, 2007
Filed:
Sep 7, 2006
Appl. No.:
11/470957
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd Carter - San Diego CA, US
Kym Lorrain - San Diego CA, US
Jammieson Pires - San Diego CA, US
Andrew Morse - San Diego CA, US
Dana Gitnick - San Marcos CA, US
Kai Treuner - San Diego CA, US
Alejandro Dearie - Chula Vista CA, US
Assignee:
BrainCells, Inc. - San Diego CA
International Classification:
A61K 38/12
A61K 31/19
US Classification:
514009000, 514575000
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on an HDac inhibitory agent alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

Gaba Receptor Mediated Modulation Of Neurogenesis

View page
US Patent:
20070112017, May 17, 2007
Filed:
Oct 30, 2006
Appl. No.:
11/554315
Inventors:
Carrolee Barlow - Del Mar CA, US
Todd Carter - San Diego CA, US
Andrew Morse - San Diego CA, US
Kym Lorrain - San Diego CA, US
Jammieson Pires - San Diego CA, US
Kai Treuner - San Diego CA, US
Assignee:
BrainCells, Inc. - San Diego CA
International Classification:
A61K 31/485
A61K 31/137
A61K 31/195
US Classification:
514282000, 514649000, 514561000
Abstract:
The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of a GABA agent, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.
Control profile
Kym I Lorrain from San Diego, CA, age ~53 Get Report